The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Abstract
Testicular cancer is relatively uncommon and accounts for <1% of all male tumors. However, it is the most common solid tumor in men between the ages of 20 and 34 years, and the global incidence has been steadily rising over the past several decades. Several risk factors for testicular cancer have been identified, including personal or family history of testicular cancer and cryptorchidism. Testicular germ cell tumors (GCTs) comprise 95% of malignant tumors arising in the testes and are categorized into 2 main histologic subtypes: seminoma and nonseminoma. Although nonseminoma is the more clinically aggressive tumor subtype, 5-year survival rates exceed 70% with current treatment options, even in patients with advanced or metastatic disease. Radical inguinal orchiectomy is the primary treatment for most patients with testicular GCTs. Postorchiectomy management is dictated by stage, histology, and risk classification; treatment options for nonseminoma include surveillance, systemic therapy, and nerve-sparing retroperitoneal lymph node dissection. Although rarely occurring, prognosis for patients with brain metastases remains poor, with >50% of patients dying within 1 year of diagnosis. This selection from the NCCN Guidelines for Testicular Cancer focuses on recommendations for the management of adult patients with nonseminomatous GCTs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
(1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.594 · Cited by 1,929
Paner, G. P., Stadler, W. M., Hansel, D. E., Montironi, R., Lin, D. W., & Amin, M. B. (2018) · European Urology · doi:10.1016/j.eururo.2017.12.018 · Cited by 621
Self-citationIncreasing Incidence of Testicular Cancer Worldwide: A Review
HUYGHE, E., MATSUDA, T., & THONNEAU, P. (2003) · Journal of Urology · doi:10.1097/01.ju.0000053866.68623.da · Cited by 605
Toxicity of platinum compounds
Hartmann, J. T., & Lipp, H.-P. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.6.889 · Cited by 604
Schmoll, H. J., Souchon, R., Krege, S., Albers, P., Beyer, J., Kollmannsberger, C., Fossa, S. D., Skakkebaek, N. E., de Wit, R., Fizazi, K., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh301 · Cited by 510
High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors
Einhorn, L. H., Williams, S. D., Chamness, A., Brames, M. J., Perkins, S. M., & Abonour, R. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067749 · Cited by 496
Cardiovascular Morbidity in Long-Term Survivors of Metastatic Testicular Cancer
Meinardi, M. T., Gietema, J. A., van der Graaf, W. T. A., van Veldhuisen, D. J., Runne, M. A., Sluiter, W. J., de Vries, E. G. E., Willemse, P. B. H., Mulder, N. H., van den Berg, M. P., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1725 · Cited by 489
Kondagunta, G. V., Bacik, J., Donadio, A., Bajorin, D., Marion, S., Sheinfeld, J., Bosl, G. J., & Motzer, R. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.19.638 · Cited by 418
Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor.
Loehrer, P. J., Gonin, R., Nichols, C. R., Weathers, T., & Einhorn, L. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.7.2500 · Cited by 397
Nichols, C. R., Catalano, P. J., Crawford, E. D., Vogelzang, N. J., Einhorn, L. H., & Loehrer, P. J. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1287 · Cited by 348
Albers, P., Siener, R., Krege, S., Schmelz, H.-U., Dieckmann, K.-P., Heidenreich, A., Kwasny, P., Pechoel, M., Lehmann, J., Kliesch, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.0899 · Cited by 337
Beyer, J., Albers, P., Altena, R., Aparicio, J., Bokemeyer, C., Busch, J., Cathomas, R., Cavallin-Stahl, E., Clarke, N. W., Claßen, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds579 · Cited by 320
International Trends in the Incidence of Testicular Cancer, 1973-2002
Chia, V. M., Quraishi, S. M., Devesa, S. S., Purdue, M. P., Cook, M. B., & McGlynn, K. A. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0031 · Cited by 303
Gilligan, T. D., Seidenfeld, J., Basch, E. M., Einhorn, L. H., Fancher, T., Smith, D. C., Stephenson, A. J., Vaughn, D. J., Cosby, R., & Hayes, D. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4481 · Cited by 297
Self-citationLorch, A., Bascoul-Mollevi, C., Kramar, A., Einhorn, L., Necchi, A., Massard, C., De Giorgi, U., Fléchon, A., Margolin, K., Lotz, J.-P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.6678 · Cited by 273
Paternity Following Treatment for Testicular Cancer
Brydøy, M., Fosså, S. D., Klepp, O., Bremnes, R. M., Wist, E. A., Wentzel-Larsen, T., & Dahl, O. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji339 · Cited by 272
Tandstad, T., Dahl, O., Cohn-Cedermark, G., Cavallin-Stahl, E., Stierner, U., Solberg, A., Langberg, C., Bremnes, R. M., Laurell, A., Wijkstrøm, H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8953 · Cited by 262
Risk of Contralateral Testicular Cancer: A Population-based Study of 29 515 U.S. Men
Fosså, S. D., Chen, J., Schonfeld, S. J., McGlynn, K. A., McMaster, M. L., Gail, M. H., & Travis, L. B. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji185 · Cited by 251
Feldman, D. R., Sheinfeld, J., Bajorin, D. F., Fischer, P., Turkula, S., Ishill, N., Patil, S., Bains, M., Reich, L. M., Bosl, G. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1561 · Cited by 239
Self-citationDaugaard, G., Gundgaard, M. G., Mortensen, M. S., Agerbæk, M., Holm, N. V., Rørth, M., von der Maase, H., Christensen, I. J., & Lauritsen, J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.5831 · Cited by 238
Strumberg, D., Brügge, S., Korn, M. W., Koeppen, S., Ranft, J., Scheiber, G., Reiners, C., Möckel, C., Seeber, S., & Scheulen, M. E. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf058 · Cited by 232
Global incidence and outcome of testicular cancer
Van Hemelrijck, M., Shanmugalingam, T., Soultati, A., Chowdhury, S., & Rudman, S. (2013) · Clinical Epidemiology · doi:10.2147/clep.s34430 · Cited by 210
Long-term toxicity of cisplatin in germ-cell tumor survivors
Chovanec, M., Abu Zaid, M., Hanna, N., El-Kouri, N., Einhorn, L. H., & Albany, C. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx360 · Cited by 204
Stephenson, A. J., Bosl, G. J., Motzer, R. J., Kattan, M. W., Stasi, J., Bajorin, D. F., & Sheinfeld, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.132 · Cited by 198
Adra, N., Einhorn, L. H., Althouse, S. K., Ammakkanavar, N. R., Musapatika, D., Albany, C., Vaughn, D., & Hanna, N. H. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx680 · Cited by 196
Self-citationSprauten, M., Darrah, T. H., Peterson, D. R., Campbell, M. E., Hannigan, R. E., Cvancarova, M., Beard, C., Haugnes, H. S., Fosså, S. D., Oldenburg, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.4025 · Cited by 170
Fertility after testicular cancer treatments
Huyghe, É., Matsuda, T., Daudin, M., et al. (2004) · Cancer · doi:10.1002/cncr.11950 · Cited by 167
Update on Late Relapse of Germ Cell Tumor: A Clinical and Molecular Analysis
George, D. W., Foster, R. S., Hromas, R. A., Robertson, K. A., Vance, G. H., Ulbright, T. M., Gobbett, T. A., Heiber, D. J., Heerema, N. A., Ramsey, H. C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.019 · Cited by 166
Predictors of Occult Metastasis in Clinical Stage I Nonseminoma: A Systematic Review
Vergouwe, Y., Steyerberg, E. W., Eijkemans, M. J. C., Albers, P., & Habbema, J. D. F. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.094 · Cited by 165
Fung, C., Dinh, P. C., Ardeshir‐Rouhani‐Fard, S., Schaffer, K. R., Fosså, S. D., & Travis, L. B. (2018) · Advances in Urology · doi:10.1155/2018/8671832 · Cited by 158
Kollmannsberger, C., Beyer, J., Liersch, R., Schoeffski, P., Metzner, B., Hartmann, J. T., Rick, O., Stengele, K., Hohloch, K., Spott, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.068 · Cited by 157
Ragni, G., Somigliana, E., Restelli, L., Salvi, R., Arnoldi, M., & Paffoni, A. (2003) · Cancer · doi:10.1002/cncr.11229 · Cited by 135
van Dijk, M. R., Steyerberg, E. W., & Habbema, J. D. F. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.043 · Cited by 132
Bokemeyer, C., Oechsle, K., Honecker, F. U., Mayer, F., Hartmann, J. T., Waller, C. F., Boehlke, I., & Kollmannsberger, C. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm526 · Cited by 132
Kerns, S. L., Fung, C., Monahan, P. O., Ardeshir‐Rouhani‐Fard, S., Zaid, M. I. A., Williams, A. M., Stump, T. E., Sesso, H. D., Feldman, D. R., Hamilton, R. J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.0735 · Cited by 127
Self-citationSALVAGE SURGERY OF CHEMOREFRACTORY GERM CELL TUMORS WITH ELEVATED TUMOR MARKERS
Albers, P., GANZ, A., HANNIG, E., Miersch, W. D. E., & MÜLLER, S. C. (2000) · The Journal of Urology · doi:10.1016/s0022-5347(05)67365-x · Cited by 119
Sturgeon, J. F. G., Moore, M. J., Kakiashvili, D., Durán, I., Anson‐Cartwright, L., Berthold, D., Warde, P. R., Gospodarowicz, M. K., Alison, R. E., Liu, J., et al. (2010) · European Urology · doi:10.1016/j.eururo.2010.12.010 · Cited by 119
Phase II study of daily oral etoposide in refractory germ cell tumors.
Miller, J. C., & Einhorn, L. H. (1990) · PubMed · Cited by 112
Greene, M. H., Kratz, C. P., Mai, P. L., Mueller, C. M., Peters, J. A., Bratslavsky, G., Ling, A. L., Choyke, P. L., Premkumar, A., Bracci, J. S., et al. (2010) · Endocrine Related Cancer · doi:10.1677/erc-09-0254 · Cited by 109
Pectasides, D., Pectasides, M., Farmakis, D. T., Aravantinos, G., Nikolaou, M., Koumpou, M., Gaglia, A., Kostopoulou, V., Mylonakis, N., & Skarlos, D.-V. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh103 · Cited by 104
Feldman, D. R., Lorch, A., Kramar, A., Albany, C., Einhorn, L. H., Giannatempo, P., Necchi, A., Fléchon, A., Boyle, H. J., Chung, P. W. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.7000 · Cited by 101
Self-citationOliver, R. T. D., Ong, J., Shamash, J., Ravi, R., Nagund, V., Harper, P., Ostrowski, M. J., Sizer, B., LeVay, J. H., Robinson, A. C. R., et al. (2004) · Urology · doi:10.1016/j.urology.2003.10.023 · Cited by 100
De Giorgi, U., Rosti, G., Aieta, M., Testore, F., Burattini, L., Fornarini, G., Naglieri, E., Lo Re, G., Zumaglini, F., & Marangolo, M. (2006) · European Urology · doi:10.1016/j.eururo.2006.05.011 · Cited by 81
Classification, epidemiology and therapies for testicular germ cell tumours
Vasdev, N., Moon, A., & Thorpe, A. C. (2013) · The International Journal of Developmental Biology · doi:10.1387/ijdb.130031nv · Cited by 79
Böhlen, D., Burkhard, F. C., Mills, R., Sonntag, R. W., & Studer, U. E. (2001) · The Journal of Urology · doi:10.1097/00005392-200102000-00022 · Cited by 68
Turnbull, C., & Rahman, N. (2011) · International Journal of Andrology · doi:10.1111/j.1365-2605.2011.01162.x · Cited by 67
Pishgar, F., Haj‐Mirzaian, A., Ebrahimi, H., Moghaddam, S. S., Mohajer, B., Nowroozi, M. R., Ayati, M., Farzadfar, F., Fitzmaurice, C., & Amini, E. (2019) · British Journal of Urology · doi:10.1111/bju.14771 · Cited by 54
Surveillance in stage I nonseminomatous germ cell tumours of the testis
Zúñiga, Á., Kakiashvili, D., & Jewett, M. A. S. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2009.08858.x · Cited by 33
Postchemotherapy Surgery for Germ Cell Tumors—What Have We Learned in 35 Years?
Riggs, S. B., Burgess, E. F., Gaston, K. E., Merwarth, C. A., & Raghavan, D. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0379 · Cited by 33
Haugnes, H. S., Stenklev, N. C., Brydøy, M., Dahl, O., Wilsgaard, T., Laukli, E., & Fosså, S. D. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1433323 · Cited by 33
Ferraro, S., Trevisiol, C., Gion, M., & Panteghini, M. (2017) · Clinical Chemistry · doi:10.1373/clinchem.2017.275263 · Cited by 27
Loriot, Y., Pagliaro, L. C., Fléchon, A., Mardiak, J., Geoffrois, L., Kerbrat, P., Chevreau, C., Delva, R., Rolland, F., Théodore, C., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.09.029 · Cited by 23
Cary, C., Jacob, J. M., Albany, C., Masterson, T. A., Hanna, N. H., Einhorn, L. H., & Foster, R. S. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.10.008 · Cited by 19
Neurotoxicity Among Survivors of Testicular Cancer: A Population-based Study
Raphael, M. J., Wei, X. S., Karim, S., Robinson, A. G., Bedard, P. L., & Booth, C. M. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.04.008 · Cited by 14
Cited by
Cancer statistics for adolescents and young adults, 2020
Miller, K. D., Fidler‐Benaoudia, M., Keegan, T. H., Hipp, H. S., Jemal, A., & Siegel, R. L. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21637 · Cited by 1,190
Annual report to the nation on the status of cancer, part I: National cancer statistics
Henley, S. J., Ward, E. M., Scott, S., Ma, J., Anderson, R. N., Firth, A. U., Thomas, C. C., Islami, F., Weir, H. K., Lewis, D. R., et al. (2020) · Cancer · doi:10.1002/cncr.32802 · Cited by 853
An Overview of PARP Inhibitors for the Treatment of Breast Cancer
Cortesi, L., Rugo, H. S., & Jackisch, C. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00796-4 · Cited by 393
Chiva, L., Zanagnolo, V., Querleu, D., Martin-Calvo, N., Arévalo-Serrano, J., Căpîlna, M. E., Fagotti, A., Kucukmetin, A., Mom, C., Chakalova, G., et al. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001506 · Cited by 295
Johns, S. A., Tarver, W. L., Secinti, E., Mosher, C. E., Stutz, P. V., Carnahan, J. L., Talib, T. L., Shanahan, M. L., Faidley, M. T., Kidwell, K. M., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103290 · Cited by 48
Metadata
- Authors
- Gilligan, T., Lin, D. W., Aggarwal, R., Chism, D., Cost, N., Derweesh, I. H., Emamekhoo, H., Feldman, D. R., Geynisman, D. M., Hancock, S. L., LaGrange, C., Levine, E. G., Longo, T., Lowrance, W., McGregor, B., Monk, P., Picus, J., Pierorazio, P., Rais-Bahrami, S., Saylor, P., Sircar, K., Smith, D. C., Tzou, K., Vaena, D., Vaughn, D., Yamoah, K., Yamzon, J., Johnson-Chilla, A., Keller, J., & Pluchino, L. A.
- Venue
- Journal of the National Comprehensive Cancer Network
- Publisher
- Harborside Press, LLC
- Published
- 2019-12
- Volume
- 17
- Issue
- 12
- Pages
- 1529-1554
- ISSN
- 1540-1405 (ISSN-L)
- 1540-1413
- OpenAlex
- W2994187593
- Cited by
- 450
- References
- 58
- FWCI
- 55.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.